Table 1.

Baseline patient characteristics (n = 24).

Median age (range)	50.1 years (31.9–74.4 years)
Race
Non-Hispanic Caucasian	16/24 (66.7%)
African–American	6/24 (25%)
Hispanic Caucasian	2/24 (8.3%)
Stage prior to treatment (as per AJCC 7th edition)
II	13/24 (54.2%)
III	11/24 (45.8%)
Nodal status prior to treatment
N0	8/24 (33.3%)
N1	10/24 (41.7%)
N2	6/24 (25%)
Genetic testing
Performed	20/24 (83.3%)
No germline mutation detected	18/20
Germline mutation detected	2/20 (both had PALB2 mutation)
Not performed	4/24 (16.7%)
Prior neoadjuvant chemotherapy
Dose dense doxorubicin + cyclophosphamide followed by paclitaxel	15/24 (62.5%)
Docetaxel + doxorubicin + cyclophosphamide	7/24 (29.2%)
Ixabepilone + doxorubicin + cyclophosphamide	1/24 (4.2%)
Ixabepilone + cetuximab + doxorubicin + cyclophosphamide	1/24 (4.2%)